ProfessorNara Medical University, Nara, JapanNara, Nara, Japan
OC 06.3 - Final Analysis Results from a Phase III Study of Emicizumab Prophylaxis for Acquired Hemophilia A (AGEHA)
Saturday, June 24, 202313:30 – 13:45 ET
PB0178 - Factor X enhances the coagulant potentials of Emicizumab.
Sunday, June 25, 202318:30 – 19:30 ET
PB0641 - Association Between Physical Activity and Bleeding Events in People with Hemophilia A Receiving Emicizumab Prophylaxis: Interim Analysis of the TSUBASA Study
Monday, June 26, 202318:30 – 19:30 ET
PB0690 - Factor X consumption could cause attenuation of emicizumab effect; A case report of severe hemophilia A with inhibitor treated by emicizumab and factor VIII-bypassing agents
PB1139 - Establishment of a novel system based on clot waveform analysis for the quick differential diagnosis of activated partial thromboplastin time (aPTT)-prolonged plasma samples
Tuesday, June 27, 202318:30 – 19:30 ET
OC 69.5 - Outcomes in Adult and Adolescent Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis From an Observational Study With Factor VIII Prophylaxis
Wednesday, June 28, 202311:15 – 11:30 ET
